Literature DB >> 17094024

Carcinoid of the rectum risk stratification (CaRRS): a strategy for preoperative outcome assessment.

Bridget N Fahy1, Laura H Tang, David Klimstra, W Douglas Wong, Jose G Guillem, Philip B Paty, Larissa K F Temple, Jinru Shia, Martin R Weiser.   

Abstract

BACKGROUND: Predicting rectal carcinoid behavior exclusively on the basis of tumor size is imprecise. We sought to identify factors associated with outcome and incorporate them into a preoperative risk stratification scheme.
METHODS: Seventy patients with rectal carcinoid evaluated at our institution were identified. Demographic, clinical, and histopathologic data were collected and correlated with recurrence and survival.
RESULTS: The mean age of our cohort was 53.6 years. Fifty-seven percent of patients were women. The mean tumor size was 1.3 cm (range, .1-5 cm). Twenty-five percent of patients had deeply invasive tumors (into the muscularis propria or deeper); an equal percentage had tumors with lymphovascular invasion (LVI) or an increased mitotic rate (two or more mitoses per 50 high-power fields). Eleven patients (17%) had distant metastases at presentation. Sixty-one patients were followed for a median of 22 months (range, 2-308 months), during which seven patients developed recurrence and seven died of disease (including two of seven whose disease recurred). Poor outcome was associated with large tumor size, deep invasion, presence of LVI, and increased mitotic rate. These factors were incorporated into a Carcinoid of the Rectum Risk Stratification (CaRRS) score. CaRRS predicted recurrence-free and disease-specific survival better than any single factor alone.
CONCLUSIONS: Poor prognostic features of rectal carcinoids include large size, deep invasion, LVI, and increased mitotic rate. The CaRRS score incorporates these features and accurately predicts outcome. Because the CaRRS score is based on values available by preoperative biopsy, it can identify patients with favorable prognosis and those with poor prognosis who may benefit from additional staging or surveillance.

Entities:  

Mesh:

Year:  2006        PMID: 17094024     DOI: 10.1245/s10434-006-9197-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; A Couvelard; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

3.  Rare anorectal neoplasms: gastrointestinal stromal tumor, carcinoid, and lymphoma.

Authors:  Elizabeth A Peralta
Journal:  Clin Colon Rectal Surg       Date:  2009-05

4.  The Ki-67 labeling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors.

Authors:  Shinya Sugimoto; Kinichi Hotta; Tadakazu Shimoda; Kenichiro Imai; Yuichiro Yamaguchi; Takashi Nakajima; Takuma Oishi; Keita Mori; Kohei Takizawa; Naomi Kakushima; Masaki Tanaka; Noboru Kawata; Hiroyuki Matsubayashi; Hiroyuki Ono
Journal:  Surg Endosc       Date:  2015-12-30       Impact factor: 4.584

5.  Treatment of colorectal carcinoids: A new paradigm.

Authors:  Tsuyoshi Konishi; Toshiaki Watanabe; Hirokazu Nagawa; Masatoshi Oya; Masashi Ueno; Hiroya Kuroyanagi; Yoshiya Fujimoto; Takashi Akiyoshi; Toshiharu Yamaguchi; Tetsuichiro Muto
Journal:  World J Gastrointest Surg       Date:  2010-05-27

6.  Surveillance strategy for rectal neuroendocrine tumors according to recurrence risk stratification.

Authors:  Dong Hyun Kim; Jin Ha Lee; Yoon Jin Cha; Soo Jung Park; Jae Hee Cheon; Tae Il Kim; Hoguen Kim; Won Ho Kim; Sung Pil Hong
Journal:  Dig Dis Sci       Date:  2013-12-10       Impact factor: 3.199

7.  Evaluation of treatment for rectal neuroendocrine tumors sized under 20 mm in comparison with the WHO 2010 guidelines.

Authors:  Nobuhisa Matsuhashi; Takao Takahashi; Hiroyuki Tomita; Hiroshi Araki; Takashi Ibuka; Kaori Tanaka; Toshiyuki Tanahashi; Satoshi Matsui; Yoshiyuki Sasaki; Yoshihiro Tanaka; Naoki Okumura; Kazuya Yamaguchi; Shinji Osada; Kazuhiro Yoshida
Journal:  Mol Clin Oncol       Date:  2017-07-18

8.  Incidence and survival patterns of rare anal canal neoplasms using the surveillance epidemiology and end results registry.

Authors:  Cristina Metildi; Elisabeth C McLemore; Thuy Tran; David Chang; Bard Cosman; Sonia L Ramamoorthy; Sidney L Saltzstein; Georgia Robins Sadler
Journal:  Am Surg       Date:  2013-10       Impact factor: 0.688

9.  Long-Term Clinical Outcomes of Rectal Neuroendocrine Tumors According to the Pathologic Status After Initial Endoscopic Resection: A KASID Multicenter Study.

Authors:  Chang Mo Moon; Kyu Chan Huh; Sung-Ae Jung; Dong Il Park; Won Hee Kim; Hye Mi Jung; Seong-Joon Koh; Jin-Oh Kim; Yunho Jung; Kyeong Ok Kim; Jong Wook Kim; Dong-Hoon Yang; Jeong Eun Shin; Sung Jae Shin; Eun Soo Kim; Young-Eun Joo
Journal:  Am J Gastroenterol       Date:  2016-07-05       Impact factor: 10.864

10.  Obturator Canal Lymph Node Metastasis from Rectal Carcinoid Tumors: Total Mesorectal Excision May Be Insufficient.

Authors:  Yi-Zarn Wang; David T Beyer; Michael Hall
Journal:  J Gastrointest Surg       Date:  2016-03-21       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.